Selected Titles
Actoverco Medical Director Stated: A Strong Commitment to the “Pharmacovigilance” System Ensures the Safety and Reliability of Actover Products
Actoverco Showcases Cardiovascular Portfolio at the 10th Joint Iranian Congress of Cardiology and Cardiovascular Surgery
The latest news and articles
Nahaleh Naraqi honors Pharmacist Day with a special message!
Nahale Naraghi honors Pharmacist Day with a special message of gratitude, recognizing the essential role pharmacists play in advancing healthcare and supporting patient well-being
Nahaleh Naraqi’s congratulatory message on the occasion of Doctor’s Day
Nahale Naraghi honors National Doctors Day in Iran, coinciding with Avicenna’s birthday.
Treatment and Reduction of Menopause Symptoms with New Drugs by “Atipharmed”
The pharmaceutical company “Atipharmed,” a subsidiary of the Actover Group, has introduced two new drugs to the national market, which are used for hormone therapy and alleviating post-menopause symptoms and issues.
Production of the first drug approved by FDA for the treatment of severe alopecia areata in Iran
Baricitinib, marketed under the brand name Actonib, is the first FDA-approved medication for the treatment of moderate to severe alopecia areata in adults.
Helping to Treat Neuropathic Pain and Anemia with an Iranian Supplement
In a ceremony attended by specialists in endocrinology, neurology, and nutrition, Nexus, a subsidiary of the Actoverco Pharmaceutical Group, unveiled its new product, “Neurostyle.”
20th Congress of Gynecologists and Obstetricians
Enthusiastic Reception by Doctors and Specialists at the 20th Congress of Gynecologists and Obstetricians
The combined diabetes medicine was produced by Iranian scientists!
Researchers at Actoverco pharmaceutical company, have succeeded in producing a type of oral combination drug for diabetes that can be used to control blood sugar in individuals with type 2 diabetes.
Actoverco launches diabetes drug “Trytis”
Actoverco pharmaceutical Group produce new drug which is named “Trytis” and it will be launched as soon.
Conferences and Exhibitions
